MAI-001 by Nanjing Minova Pharmaceutical Technology for Depression: Likelihood of Approval

MAI-001 is under clinical development by Nanjing Minova Pharmaceutical Technology and currently in Phase I for Depression.

Rad AI Secures $60M for Generative AI Solutions for Radiology

What You Should Know: – Rad AI, one of the fastest-growing healthcare AI companies and the first to develop a large language model in healthcare, today

January 30, 2025

FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use

The FDA is warning consumers not to use counterfeit Ozempic after it found thousands of units of fake product in the supply chain. The agency

December 29, 2023

Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

SEOUL, South Korea — Combining the novel anti-TIGIT monoclonal antibody tiragolumab with atezolizumab (Tecentriq) to treat PD-L1-positive recurrent cervical cancer didn’t improve overall response rate

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.